Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
|---|---|---|---|---|---|
| AN3-H5253 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, Fc Tag |  |
|
|
| AN3-H52H3 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag |  |
|
|
| AN3-M52H3 | Mouse | Mouse Angiopoietin-like 3 / ANGPTL3 Protein, His Tag |  |
|
|
| AN3-H82E7 | Human | Biotinylated Human Angiopoietin-like 3 / ANGPTL3 Protein, His,Avitag™ |  |
|
|
| AN3-H5226 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag |  |
|
Immobilized Human Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.5-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Evinacumab | REGN-1500 | Approved | Regeneron Pharmaceuticals Inc | Evkeeza | United States | Hypercholesterolemia; Homozygous familial hypercholesterolemia | Regeneron Pharmaceuticals Inc | 2021-02-11 | Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SHR-1918 | SHR-1918; SHR1918 | Phase 3 Clinical | Beijing Suncadia Medicine Co Ltd | Homozygous familial hypercholesterolemia; Hyperlipidemias | Details |
| Zodasiran | ARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals) | Phase 3 Clinical | Roche Ltd | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Dyslipidemias; Hyperlipoproteinemia Type II | Details |
| LNA-043 | LNA-043 | Phase 2 Clinical | Novartis Pharma Ag | Knee Injuries; Osteoarthritis, Knee; Osteoarthritis | Details |
| Vupanorsen | ISIS-703802; PF-07285557 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hyperlipoproteinemia Type I; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Hyperlipoproteinemia Type II; Hyperlipidemias | Details |
| Solbinsiran | LY-3561774; DCR-CM-1; DCR-CM1 | Phase 2 Clinical | Dicerna Pharmaceuticals Inc | Metabolic Diseases; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Lipid Metabolism Disorders | Details |
| LY-3475766 | LY-3475766 | Phase 1 Clinical | Eli Lilly And Company | Dyslipidemias | Details |
| JS-401 | JS-401 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Hyperlipidemias | Details |
| VERVE-201 | VERVE-201 | Phase 1 Clinical | Broad Institute, Harvard University | Homozygous familial hypercholesterolemia; Atherosclerosis; Hypercholesterolemia | Details |
| NN-6491 | NN6491; NN-6491 | Phase 1 Clinical | Novo Nordisk A/S | Cardiovascular Diseases | Details |
| NNC0491-6075 | NNC0491-6075; NNC04916075 | Phase 1 Clinical | Novo Nordisk A/S | Dyslipidemias | Details |
| RP-912 | RP-912; RP912 | Phase 1 Clinical | Runjia (Shanghai) Pharmaceutical Technology Co Ltd | Metabolic Diseases | Details |
| AZD-1705 | AZD1705; AZD-1705 | Phase 1 Clinical | Parexel, Astrazeneca Plc | Cardiovascular Diseases | Details |
This web search service is supported by Google Inc.
A-Z
